EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research

Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A Wellberg

Journal of Clinical Investigation · 03.11.2025 · 135 (21)

DOI: 10.1172/jci194743 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.11.2025. Verfasst von Estefania Valencia-Rincón und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, College of Medicine, and. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Neoplasms, Translational Research, Biomedical, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer diagnoses are prevalent in people with obesity and type 2 diabetes, and abundant clinical evidence supports the protective effects of weight loss for cancer prevention. Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized obesity and type 2 diabetes medicine and alleviate many comorbidities of these metabolic diseases. In this Review, we summarize the current clinical evidence for GLP-1 receptor agonists and cancer risk, including thyroid, pancreatic, gastrointestinal, and hormone-dependent malignancies. With few exceptions, recent meta-analyses report that GLP-1 receptor therapies do not increase cancer incidence and may lower risk in some cases. Preclinical studies reinforce the anticancer effects of GLP-1 receptor therapies, even in non-obese models. However, there are still many opportunities for translational insight as the field grows. Immune-modulating effects of GLP-1 receptor agonists are reported in several preclinical cancer studies, which may reflect direct action on immune cells or result from improved metabolic function. We highlight ongoing clinical trials for GLP-1 receptor therapies in cancer patients, and offer considerations for preclinical studies, including perspectives on the timing and duration of GLP-1 receptor agonist treatment, concurrent use of standard anticancer therapies, and interpretation of models of cancer risk versus progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsNeoplasmsTranslational Research, BiomedicalDiabetes Mellitus, Type 2HumansAnimalsGlucagon-Like Peptide-1 ReceptorObesity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorGLP1R protein, human

Autor:innen und Institutionen

  • Department of Pathology, College of Medicine, and.
  • Gynecologic Oncology Section, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.

Zitieren

APA

Valencia-Rincón, E., Rai, R., Chandra, V., & Wellberg, E. A. (2025). GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. Journal of Clinical Investigation, 135(21). https://doi.org/10.1172/jci194743

Vancouver

Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. Journal of Clinical Investigation. 2025;135(21). doi:10.1172/jci194743

BibTeX
@article{ValenciaRincn2025,
  author = {Valencia-Rincón, Estefania and Rai, Rajani and Chandra, Vishal and Wellberg, Elizabeth A},
  title = {GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {21},
  doi = {10.1172/jci194743}
}
Kostenlos starten →